| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 44 | 2016 | 1033 | 3.340 |
Why?
|
| Genetic Linkage | 41 | 2012 | 299 | 3.050 |
Why?
|
| Polymorphism, Single Nucleotide | 66 | 2025 | 2175 | 3.000 |
Why?
|
| Genetic Predisposition to Disease | 69 | 2025 | 2416 | 2.860 |
Why?
|
| Genome-Wide Association Study | 47 | 2025 | 1434 | 2.620 |
Why?
|
| Genotype | 52 | 2023 | 1906 | 1.410 |
Why?
|
| Genome, Human | 17 | 2020 | 422 | 1.320 |
Why?
|
| Gene Frequency | 33 | 2022 | 521 | 1.320 |
Why?
|
| Genetic Variation | 26 | 2021 | 986 | 1.180 |
Why?
|
| Chromosomes, Human, Pair 17 | 11 | 2019 | 55 | 0.960 |
Why?
|
| Cardiovascular Diseases | 17 | 2022 | 2110 | 0.930 |
Why?
|
| Body Mass Index | 20 | 2025 | 2351 | 0.900 |
Why?
|
| Exome | 9 | 2016 | 231 | 0.880 |
Why?
|
| Obesity | 16 | 2025 | 2966 | 0.810 |
Why?
|
| Alleles | 21 | 2025 | 888 | 0.810 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2025 | 279 | 0.810 |
Why?
|
| Neuroimaging | 1 | 2025 | 291 | 0.790 |
Why?
|
| Haplotypes | 26 | 2016 | 487 | 0.790 |
Why?
|
| Chromosome Mapping | 25 | 2010 | 523 | 0.770 |
Why?
|
| Genetic Loci | 10 | 2019 | 288 | 0.720 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2025 | 578 | 0.710 |
Why?
|
| Male | 140 | 2025 | 67308 | 0.710 |
Why?
|
| Models, Genetic | 14 | 2022 | 607 | 0.700 |
Why?
|
| Hypertension | 7 | 2022 | 1291 | 0.700 |
Why?
|
| Middle Aged | 83 | 2025 | 33118 | 0.670 |
Why?
|
| Humans | 193 | 2025 | 136899 | 0.640 |
Why?
|
| Aged | 73 | 2025 | 23641 | 0.640 |
Why?
|
| Pedigree | 25 | 2016 | 509 | 0.640 |
Why?
|
| Sickle Cell Trait | 4 | 2020 | 13 | 0.620 |
Why?
|
| Polymorphism, Genetic | 9 | 2009 | 652 | 0.610 |
Why?
|
| Genetic Association Studies | 9 | 2022 | 377 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 2019 | 36 | 0.580 |
Why?
|
| Phenotype | 27 | 2025 | 3201 | 0.550 |
Why?
|
| Adult | 77 | 2025 | 37595 | 0.540 |
Why?
|
| Apolipoproteins E | 3 | 2015 | 84 | 0.530 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2025 | 2508 | 0.520 |
Why?
|
| Female | 116 | 2025 | 72703 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2015 | 54 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 11 | 11 | 2011 | 59 | 0.480 |
Why?
|
| Fibroblast Growth Factor 5 | 1 | 2015 | 2 | 0.470 |
Why?
|
| Plasma Membrane Calcium-Transporting ATPases | 1 | 2015 | 11 | 0.470 |
Why?
|
| Lipoprotein(a) | 1 | 2015 | 67 | 0.460 |
Why?
|
| Transferrin | 1 | 2014 | 47 | 0.450 |
Why?
|
| Trinucleotide Repeats | 2 | 2008 | 25 | 0.450 |
Why?
|
| Ferritins | 1 | 2014 | 65 | 0.450 |
Why?
|
| src-Family Kinases | 1 | 2015 | 94 | 0.440 |
Why?
|
| Receptors, Androgen | 3 | 2017 | 149 | 0.440 |
Why?
|
| Quantitative Trait, Heritable | 9 | 2021 | 126 | 0.440 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2014 | 59 | 0.430 |
Why?
|
| Family Health | 10 | 2017 | 200 | 0.420 |
Why?
|
| Quantitative Trait Loci | 9 | 2022 | 381 | 0.420 |
Why?
|
| Blood Pressure | 5 | 2020 | 1774 | 0.410 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2017 | 84 | 0.410 |
Why?
|
| Lod Score | 16 | 2011 | 67 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 3710 | 0.400 |
Why?
|
| Ataxia Telangiectasia | 10 | 2004 | 20 | 0.390 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2024 | 608 | 0.390 |
Why?
|
| Iron | 1 | 2014 | 313 | 0.380 |
Why?
|
| Whole Genome Sequencing | 2 | 2025 | 152 | 0.380 |
Why?
|
| Microsatellite Repeats | 11 | 2012 | 168 | 0.370 |
Why?
|
| Cohort Studies | 23 | 2025 | 5711 | 0.370 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2021 | 15 | 0.360 |
Why?
|
| Blood Coagulation | 2 | 2015 | 254 | 0.350 |
Why?
|
| Control Groups | 1 | 2010 | 11 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 19 | 0.350 |
Why?
|
| Risk Factors | 26 | 2024 | 10313 | 0.340 |
Why?
|
| Weight Gain | 5 | 2016 | 518 | 0.340 |
Why?
|
| Proteins | 7 | 2022 | 1012 | 0.340 |
Why?
|
| Young Adult | 24 | 2025 | 13157 | 0.330 |
Why?
|
| X Chromosome | 2 | 2000 | 53 | 0.330 |
Why?
|
| Longitudinal Studies | 15 | 2022 | 2844 | 0.330 |
Why?
|
| Genes, BRCA1 | 3 | 2004 | 38 | 0.320 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 207 | 0.320 |
Why?
|
| Germ-Line Mutation | 6 | 2020 | 171 | 0.310 |
Why?
|
| Genetics, Population | 8 | 2021 | 206 | 0.310 |
Why?
|
| Malocclusion, Angle Class III | 1 | 2009 | 2 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2009 | 36 | 0.310 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 73 | 0.310 |
Why?
|
| C-Reactive Protein | 5 | 2020 | 409 | 0.310 |
Why?
|
| Linkage Disequilibrium | 12 | 2017 | 268 | 0.310 |
Why?
|
| Glomerular Filtration Rate | 5 | 2024 | 739 | 0.310 |
Why?
|
| Prospective Studies | 15 | 2025 | 7543 | 0.300 |
Why?
|
| Atherosclerosis | 4 | 2022 | 411 | 0.300 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 7552 | 0.300 |
Why?
|
| Genetic Markers | 19 | 2017 | 345 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2016 | 328 | 0.280 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2021 | 86 | 0.270 |
Why?
|
| Adiponectin | 5 | 2011 | 241 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 556 | 0.260 |
Why?
|
| Veterans | 3 | 2023 | 1446 | 0.260 |
Why?
|
| CpG Islands | 2 | 2024 | 160 | 0.260 |
Why?
|
| Case-Control Studies | 16 | 2023 | 3528 | 0.260 |
Why?
|
| Fibrinolysis | 1 | 2008 | 143 | 0.260 |
Why?
|
| Genetic Pleiotropy | 2 | 2016 | 31 | 0.250 |
Why?
|
| Age of Onset | 6 | 2014 | 520 | 0.250 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 390 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2006 | 56 | 0.250 |
Why?
|
| Adolescent | 29 | 2025 | 21402 | 0.240 |
Why?
|
| Mutation, Missense | 7 | 2018 | 338 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 20 | 4 | 2011 | 17 | 0.240 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2023 | 50 | 0.240 |
Why?
|
| Kidney | 3 | 2023 | 1460 | 0.230 |
Why?
|
| Apolipoprotein L1 | 2 | 2023 | 13 | 0.230 |
Why?
|
| Genetic Techniques | 2 | 2004 | 64 | 0.230 |
Why?
|
| Inheritance Patterns | 1 | 2004 | 47 | 0.230 |
Why?
|
| Observer Variation | 1 | 2025 | 343 | 0.220 |
Why?
|
| Sequence Analysis, DNA | 7 | 2016 | 811 | 0.220 |
Why?
|
| Fasting | 4 | 2018 | 276 | 0.220 |
Why?
|
| DNA Methylation | 3 | 2024 | 644 | 0.220 |
Why?
|
| Homocysteine | 2 | 2018 | 155 | 0.220 |
Why?
|
| Coronary Artery Disease | 4 | 2018 | 701 | 0.210 |
Why?
|
| Genetics | 1 | 2004 | 27 | 0.210 |
Why?
|
| United States | 24 | 2020 | 14595 | 0.210 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2023 | 47 | 0.210 |
Why?
|
| Blood Glucose | 6 | 2021 | 2161 | 0.210 |
Why?
|
| Homeodomain Proteins | 3 | 2012 | 504 | 0.200 |
Why?
|
| Mississippi | 3 | 2021 | 21 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 1 | 5 | 2009 | 73 | 0.200 |
Why?
|
| Chronic Periodontitis | 2 | 2013 | 5 | 0.200 |
Why?
|
| Dementia, Vascular | 1 | 2022 | 20 | 0.200 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 703 | 0.200 |
Why?
|
| Life Style | 1 | 2025 | 480 | 0.200 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 94 | 0.200 |
Why?
|
| DNA, Neoplasm | 5 | 2014 | 165 | 0.190 |
Why?
|
| Software | 4 | 2016 | 670 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 8 | 2012 | 1061 | 0.190 |
Why?
|
| Multifactorial Inheritance | 4 | 2025 | 174 | 0.190 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2022 | 130 | 0.190 |
Why?
|
| Obesity, Morbid | 1 | 2025 | 257 | 0.180 |
Why?
|
| Aging, Premature | 1 | 2021 | 13 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 328 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2012 | 36 | 0.180 |
Why?
|
| Chromosomes, Human, X | 3 | 2015 | 75 | 0.180 |
Why?
|
| Smoking | 2 | 2021 | 1633 | 0.180 |
Why?
|
| Phenylketonurias | 1 | 2021 | 15 | 0.180 |
Why?
|
| Age Factors | 12 | 2021 | 3290 | 0.170 |
Why?
|
| Linear Models | 4 | 2021 | 850 | 0.170 |
Why?
|
| Receptors, Adiponectin | 2 | 2011 | 19 | 0.170 |
Why?
|
| Risk Assessment | 11 | 2021 | 3432 | 0.170 |
Why?
|
| Nutrition Surveys | 4 | 2018 | 267 | 0.170 |
Why?
|
| Epigenomics | 1 | 2021 | 115 | 0.170 |
Why?
|
| Carcinoma | 3 | 2010 | 237 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 1945 | 0.170 |
Why?
|
| Mutation | 9 | 2014 | 3948 | 0.170 |
Why?
|
| Epigenesis, Genetic | 2 | 2024 | 658 | 0.170 |
Why?
|
| Prognosis | 9 | 2021 | 4011 | 0.160 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 39 | 0.160 |
Why?
|
| Zinc Fingers | 2 | 2017 | 50 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 10 | 0.160 |
Why?
|
| Statistics, Nonparametric | 4 | 2017 | 434 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2022 | 524 | 0.160 |
Why?
|
| Adiposity | 2 | 2017 | 517 | 0.160 |
Why?
|
| Biomarkers | 7 | 2023 | 4148 | 0.160 |
Why?
|
| Factor VIII | 1 | 2020 | 99 | 0.160 |
Why?
|
| Exercise | 4 | 2016 | 2015 | 0.160 |
Why?
|
| Genetic Testing | 4 | 2009 | 453 | 0.160 |
Why?
|
| DNA-Binding Proteins | 7 | 2020 | 1502 | 0.160 |
Why?
|
| Computer Simulation | 6 | 2021 | 984 | 0.160 |
Why?
|
| Pediatric Obesity | 2 | 2017 | 588 | 0.160 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 157 | 0.160 |
Why?
|
| Repressor Proteins | 3 | 2014 | 424 | 0.150 |
Why?
|
| Trabeculectomy | 1 | 2000 | 72 | 0.150 |
Why?
|
| International Cooperation | 5 | 2011 | 198 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 133 | 0.150 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 73 | 0.150 |
Why?
|
| Mortality | 1 | 2021 | 357 | 0.150 |
Why?
|
| Incidence | 7 | 2021 | 2783 | 0.150 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 614 | 0.150 |
Why?
|
| Lymphoma | 1 | 2020 | 207 | 0.150 |
Why?
|
| Adolescent Health | 2 | 2015 | 42 | 0.150 |
Why?
|
| Fibrinogen | 2 | 2010 | 170 | 0.150 |
Why?
|
| alpha-Globins | 1 | 2018 | 9 | 0.150 |
Why?
|
| Hemoglobin, Sickle | 1 | 2018 | 18 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 115 | 0.150 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 3282 | 0.150 |
Why?
|
| China | 2 | 2018 | 218 | 0.140 |
Why?
|
| Thromboplastin | 2 | 2017 | 74 | 0.140 |
Why?
|
| Gene Pool | 1 | 2017 | 5 | 0.140 |
Why?
|
| Antithrombin III | 1 | 2017 | 13 | 0.140 |
Why?
|
| Child | 19 | 2022 | 21896 | 0.140 |
Why?
|
| Receptors, LDL | 2 | 2014 | 49 | 0.140 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 1262 | 0.140 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2017 | 11 | 0.140 |
Why?
|
| Health Surveys | 2 | 2018 | 520 | 0.140 |
Why?
|
| Brain Ischemia | 2 | 2015 | 341 | 0.140 |
Why?
|
| Mitral Valve Prolapse | 1 | 2017 | 9 | 0.140 |
Why?
|
| Factor VIIa | 1 | 2017 | 41 | 0.140 |
Why?
|
| Gene Expression | 1 | 2022 | 1505 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2020 | 239 | 0.140 |
Why?
|
| Asthma | 5 | 2019 | 2285 | 0.140 |
Why?
|
| Body Height | 2 | 2017 | 201 | 0.140 |
Why?
|
| Leukocytes | 2 | 2016 | 311 | 0.140 |
Why?
|
| Proteome | 1 | 2022 | 473 | 0.140 |
Why?
|
| Escherichia coli O104 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Blood Platelets | 2 | 2016 | 405 | 0.130 |
Why?
|
| Logistic Models | 4 | 2025 | 2060 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2020 | 790 | 0.130 |
Why?
|
| Glaucoma | 1 | 2000 | 234 | 0.130 |
Why?
|
| Cattle Diseases | 1 | 2016 | 24 | 0.130 |
Why?
|
| Schizophrenia | 5 | 2007 | 446 | 0.130 |
Why?
|
| Erythropoiesis | 1 | 2016 | 54 | 0.130 |
Why?
|
| Cadmium | 1 | 2016 | 70 | 0.130 |
Why?
|
| Immune System Diseases | 1 | 2016 | 39 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2009 | 316 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 493 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 111 | 0.120 |
Why?
|
| Motivation | 1 | 2021 | 570 | 0.120 |
Why?
|
| Factor XII | 1 | 2015 | 6 | 0.120 |
Why?
|
| Chromosomes, Human, Y | 1 | 2015 | 23 | 0.120 |
Why?
|
| Disease | 1 | 2016 | 98 | 0.120 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2015 | 7 | 0.120 |
Why?
|
| Algorithms | 3 | 2021 | 1695 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 765 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 689 | 0.120 |
Why?
|
| Laminin | 1 | 2015 | 69 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 84 | 0.120 |
Why?
|
| Microbiota | 1 | 2023 | 763 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 2 | 2013 | 218 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2014 | 362 | 0.120 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 5398 | 0.120 |
Why?
|
| Menarche | 1 | 2015 | 60 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 193 | 0.120 |
Why?
|
| Mutation Rate | 1 | 2015 | 28 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2012 | 30 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2019 | 21 | 0.120 |
Why?
|
| Motor Activity | 2 | 2013 | 722 | 0.120 |
Why?
|
| Apolipoproteins A | 1 | 2014 | 19 | 0.120 |
Why?
|
| Epistasis, Genetic | 1 | 2015 | 71 | 0.120 |
Why?
|
| Energy Intake | 1 | 2017 | 473 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2015 | 171 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2019 | 645 | 0.110 |
Why?
|
| Energy Metabolism | 2 | 2017 | 892 | 0.110 |
Why?
|
| Thrombin | 1 | 2015 | 152 | 0.110 |
Why?
|
| Africa | 2 | 2020 | 109 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2016 | 1167 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2021 | 1187 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 266 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 201 | 0.110 |
Why?
|
| Germany | 4 | 2021 | 121 | 0.110 |
Why?
|
| CD36 Antigens | 1 | 2014 | 36 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2013 | 29 | 0.110 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 193 | 0.110 |
Why?
|
| Penetrance | 2 | 2015 | 28 | 0.110 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 21 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 181 | 0.110 |
Why?
|
| Philippines | 5 | 2011 | 51 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2016 | 350 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 429 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2017 | 310 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1689 | 0.100 |
Why?
|
| Blood Cells | 1 | 2012 | 40 | 0.100 |
Why?
|
| Periodontium | 1 | 2012 | 3 | 0.100 |
Why?
|
| Time Factors | 6 | 2021 | 6802 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 4 | 2014 | 179 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 253 | 0.100 |
Why?
|
| Autoantigens | 1 | 2015 | 429 | 0.100 |
Why?
|
| Interleukin-18 | 1 | 2013 | 237 | 0.100 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 104 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 3 | 2006 | 1255 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 620 | 0.100 |
Why?
|
| Methyltransferases | 1 | 2012 | 76 | 0.090 |
Why?
|
| Arsenic | 1 | 2012 | 66 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 30 | 0.090 |
Why?
|
| Receptors, Immunologic | 2 | 2003 | 223 | 0.090 |
Why?
|
| Factor VII | 1 | 2011 | 24 | 0.090 |
Why?
|
| Metagenome | 1 | 2012 | 147 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 424 | 0.090 |
Why?
|
| Sample Size | 3 | 2021 | 118 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2010 | 45 | 0.090 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 606 | 0.090 |
Why?
|
| Homozygote | 3 | 2012 | 203 | 0.090 |
Why?
|
| Kininogen, Low-Molecular-Weight | 1 | 2010 | 2 | 0.090 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2010 | 3 | 0.090 |
Why?
|
| Kininogens | 1 | 2010 | 6 | 0.090 |
Why?
|
| Mathematical Computing | 1 | 2010 | 11 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2016 | 692 | 0.090 |
Why?
|
| TCF Transcription Factors | 1 | 2010 | 17 | 0.090 |
Why?
|
| Indians, North American | 1 | 2016 | 624 | 0.090 |
Why?
|
| Cystic Fibrosis | 2 | 2011 | 1088 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2004 | 2243 | 0.080 |
Why?
|
| Population | 1 | 2010 | 35 | 0.080 |
Why?
|
| Nandrolone | 1 | 2010 | 3 | 0.080 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2010 | 4 | 0.080 |
Why?
|
| Malawi | 1 | 2010 | 53 | 0.080 |
Why?
|
| Ethinyl Estradiol | 1 | 2010 | 16 | 0.080 |
Why?
|
| Family | 4 | 2006 | 667 | 0.080 |
Why?
|
| Molecular Epidemiology | 2 | 2022 | 67 | 0.080 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 34 | 0.080 |
Why?
|
| Carbohydrate Metabolism | 1 | 2010 | 63 | 0.080 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 3 | 2016 | 26 | 0.080 |
Why?
|
| RNA Helicases | 1 | 2009 | 30 | 0.080 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2009 | 52 | 0.080 |
Why?
|
| Heterozygote | 3 | 2016 | 291 | 0.080 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2009 | 2 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 1044 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2210 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 250 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 50 | 0.080 |
Why?
|
| Maxilla | 1 | 2009 | 36 | 0.080 |
Why?
|
| Cephalometry | 1 | 2009 | 33 | 0.080 |
Why?
|
| Genes, Recessive | 4 | 2004 | 78 | 0.080 |
Why?
|
| Glucose Intolerance | 1 | 2010 | 146 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 205 | 0.080 |
Why?
|
| Genes, Homeobox | 1 | 2009 | 50 | 0.080 |
Why?
|
| Collagen Type II | 1 | 2009 | 53 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 99 | 0.070 |
Why?
|
| Stroke | 2 | 2015 | 1122 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 2 | 2007 | 161 | 0.070 |
Why?
|
| Oxidoreductases | 1 | 2009 | 93 | 0.070 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2008 | 7 | 0.070 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2009 | 108 | 0.070 |
Why?
|
| Psoriasis | 2 | 2002 | 102 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 26 | 0.070 |
Why?
|
| Adolescent Behavior | 1 | 2013 | 536 | 0.070 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2008 | 29 | 0.070 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2020 | 104 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 86 | 0.070 |
Why?
|
| HLA-DR2 Antigen | 1 | 2007 | 7 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2012 | 571 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 158 | 0.070 |
Why?
|
| Genes, Dominant | 2 | 2004 | 95 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2009 | 771 | 0.070 |
Why?
|
| Prediabetic State | 1 | 2010 | 247 | 0.070 |
Why?
|
| HLA-DR3 Antigen | 1 | 2007 | 80 | 0.070 |
Why?
|
| BRCA1 Protein | 1 | 2007 | 76 | 0.070 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2006 | 32 | 0.070 |
Why?
|
| Europe | 1 | 2008 | 413 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2006 | 11 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2006 | 12 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2009 | 311 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 536 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2006 | 44 | 0.060 |
Why?
|
| Genes, Lethal | 1 | 2005 | 30 | 0.060 |
Why?
|
| Pimozide | 2 | 1976 | 4 | 0.060 |
Why?
|
| Genomic Imprinting | 1 | 2005 | 26 | 0.060 |
Why?
|
| Sex Factors | 5 | 2017 | 2067 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2012 | 1715 | 0.060 |
Why?
|
| National Longitudinal Study of Adolescent Health | 2 | 2016 | 9 | 0.060 |
Why?
|
| Infant | 5 | 2010 | 9408 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 5126 | 0.060 |
Why?
|
| Genomics | 2 | 2007 | 790 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 892 | 0.060 |
Why?
|
| Warfarin | 1 | 2006 | 149 | 0.060 |
Why?
|
| Chromosomes | 1 | 2005 | 108 | 0.060 |
Why?
|
| Multigene Family | 1 | 2005 | 202 | 0.060 |
Why?
|
| Population Groups | 1 | 2025 | 63 | 0.060 |
Why?
|
| Serum | 1 | 2005 | 59 | 0.060 |
Why?
|
| Platelet Count | 2 | 2016 | 85 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 1320 | 0.060 |
Why?
|
| Immunoglobulin E | 2 | 2003 | 337 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 437 | 0.060 |
Why?
|
| Hematocrit | 2 | 2016 | 95 | 0.060 |
Why?
|
| Lung Diseases | 1 | 2011 | 768 | 0.060 |
Why?
|
| Siblings | 3 | 2010 | 228 | 0.060 |
Why?
|
| Fertility | 1 | 2005 | 160 | 0.060 |
Why?
|
| Receptor, Melanocortin, Type 4 | 2 | 2016 | 19 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 256 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 510 | 0.050 |
Why?
|
| Michigan | 3 | 2012 | 108 | 0.050 |
Why?
|
| Apolipoproteins | 1 | 2023 | 33 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2005 | 208 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 28 | 0.050 |
Why?
|
| Syndrome | 3 | 2017 | 359 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 401 | 0.050 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2003 | 44 | 0.050 |
Why?
|
| Meiosis | 1 | 2004 | 81 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2023 | 48 | 0.050 |
Why?
|
| Asialoglycoprotein Receptor | 1 | 2022 | 7 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 132 | 0.050 |
Why?
|
| Tropomyosin | 1 | 2002 | 14 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2007 | 816 | 0.050 |
Why?
|
| Insulin | 4 | 2021 | 2389 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2007 | 517 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2022 | 62 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2022 | 1684 | 0.050 |
Why?
|
| Endoribonucleases | 1 | 2003 | 80 | 0.050 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 255 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2016 | 356 | 0.050 |
Why?
|
| Genome | 1 | 2004 | 292 | 0.050 |
Why?
|
| Inflammation | 2 | 2013 | 2817 | 0.050 |
Why?
|
| Risk | 3 | 2010 | 905 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2002 | 93 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 2744 | 0.050 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2002 | 83 | 0.050 |
Why?
|
| Amino Acid Substitution | 3 | 2012 | 309 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2015 | 352 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 126 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2006 | 662 | 0.040 |
Why?
|
| Netherlands | 1 | 2021 | 88 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 934 | 0.040 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 11 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2006 | 1271 | 0.040 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 40 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2021 | 157 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2002 | 237 | 0.040 |
Why?
|
| Platelet Factor 4 | 1 | 1980 | 35 | 0.040 |
Why?
|
| Mitogens | 1 | 1980 | 61 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 28 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 202 | 0.040 |
Why?
|
| Disease Susceptibility | 4 | 2009 | 344 | 0.040 |
Why?
|
| Growth Substances | 1 | 1980 | 148 | 0.040 |
Why?
|
| Blood Coagulation Factors | 1 | 1980 | 54 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 54 | 0.040 |
Why?
|
| Codon, Nonsense | 2 | 2015 | 44 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 2 | 2017 | 183 | 0.040 |
Why?
|
| Africa, Western | 1 | 2020 | 17 | 0.040 |
Why?
|
| Body Weight | 3 | 2010 | 973 | 0.040 |
Why?
|
| Calcinosis | 1 | 2002 | 233 | 0.040 |
Why?
|
| United Kingdom | 1 | 2021 | 322 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2003 | 284 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2003 | 291 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 1376 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2020 | 80 | 0.040 |
Why?
|
| Albuminuria | 1 | 2020 | 185 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2004 | 667 | 0.040 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2020 | 91 | 0.040 |
Why?
|
| Idarubicin | 1 | 2019 | 5 | 0.040 |
Why?
|
| Exons | 3 | 2006 | 349 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2016 | 405 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2007 | 1498 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 308 | 0.040 |
Why?
|
| Abdomen | 1 | 2019 | 125 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 74 | 0.040 |
Why?
|
| Creatinine | 1 | 2020 | 500 | 0.040 |
Why?
|
| Cognition | 1 | 2006 | 1189 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2017 | 6043 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 152 | 0.040 |
Why?
|
| Chromosome Breakage | 1 | 1998 | 23 | 0.040 |
Why?
|
| alpha-Thalassemia | 1 | 2018 | 4 | 0.040 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2018 | 11 | 0.040 |
Why?
|
| Brain | 3 | 2007 | 2828 | 0.040 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2017 | 5 | 0.040 |
Why?
|
| Prostate | 2 | 2012 | 175 | 0.040 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Pregnancy | 3 | 2021 | 6715 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 690 | 0.040 |
Why?
|
| Azacitidine | 1 | 2019 | 141 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 10768 | 0.030 |
Why?
|
| Research Design | 1 | 2004 | 1108 | 0.030 |
Why?
|
| Pseudorabies | 1 | 1997 | 1 | 0.030 |
Why?
|
| Herpesvirus 1, Suid | 1 | 1997 | 2 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 560 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2000 | 305 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 455 | 0.030 |
Why?
|
| Homeostasis | 1 | 2021 | 622 | 0.030 |
Why?
|
| Cytokines | 1 | 2005 | 2078 | 0.030 |
Why?
|
| ADAMTS Proteins | 1 | 2017 | 5 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2017 | 8 | 0.030 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 1 | 2017 | 4 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2017 | 8 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 398 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 1997 | 28 | 0.030 |
Why?
|
| DNA | 2 | 2022 | 1460 | 0.030 |
Why?
|
| Somatomedins | 1 | 2017 | 27 | 0.030 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 182 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 646 | 0.030 |
Why?
|
| Body Burden | 1 | 2016 | 8 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2016 | 43 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2019 | 493 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 37 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2017 | 316 | 0.030 |
Why?
|
| Autopsy | 1 | 1997 | 94 | 0.030 |
Why?
|
| Muridae | 1 | 1996 | 5 | 0.030 |
Why?
|
| Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2016 | 9 | 0.030 |
Why?
|
| Transcription Factor AP-2 | 1 | 2016 | 83 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 110 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 43 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2017 | 84 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2016 | 29 | 0.030 |
Why?
|
| Drosophila | 1 | 2017 | 146 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2020 | 413 | 0.030 |
Why?
|
| Transportation | 1 | 2016 | 51 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2017 | 107 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 54 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1130 | 0.030 |
Why?
|
| Homicide | 1 | 1997 | 66 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 179 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1057 | 0.030 |
Why?
|
| Quality Control | 1 | 2016 | 171 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1018 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2016 | 99 | 0.030 |
Why?
|
| Chromosomes, Human | 2 | 2009 | 44 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 316 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2019 | 632 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2020 | 624 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2021 | 2615 | 0.030 |
Why?
|
| Parents | 1 | 2004 | 1361 | 0.030 |
Why?
|
| Genes, X-Linked | 1 | 2015 | 18 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 195 | 0.030 |
Why?
|
| Diet | 1 | 2023 | 1261 | 0.030 |
Why?
|
| Normal Distribution | 1 | 2015 | 22 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 33 | 0.030 |
Why?
|
| Apolipoprotein A-V | 1 | 2014 | 3 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 379 | 0.030 |
Why?
|
| Prevalence | 2 | 2013 | 2709 | 0.030 |
Why?
|
| Amides | 1 | 2015 | 93 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 345 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2015 | 88 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 543 | 0.030 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 1995 | 41 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 75 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 2901 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 362 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 391 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 378 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 471 | 0.030 |
Why?
|
| Birth Weight | 1 | 2017 | 514 | 0.030 |
Why?
|
| Echocardiography | 1 | 2017 | 659 | 0.030 |
Why?
|
| Animals | 8 | 2017 | 36915 | 0.030 |
Why?
|
| Genetic Code | 1 | 2014 | 21 | 0.030 |
Why?
|
| Proprotein Convertases | 1 | 2014 | 16 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 463 | 0.030 |
Why?
|
| Mothers | 2 | 2010 | 752 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 982 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 2143 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2014 | 73 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2009 | 11013 | 0.030 |
Why?
|
| Lipase | 1 | 2014 | 68 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 463 | 0.030 |
Why?
|
| Video Games | 1 | 2013 | 27 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 123 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 374 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 477 | 0.030 |
Why?
|
| Scavenger Receptors, Class A | 2 | 2003 | 12 | 0.030 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 1993 | 56 | 0.030 |
Why?
|
| Receptors, Scavenger | 2 | 2003 | 25 | 0.030 |
Why?
|
| Hexosyltransferases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Television | 1 | 2013 | 75 | 0.030 |
Why?
|
| International Agencies | 1 | 2012 | 35 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2003 | 328 | 0.020 |
Why?
|
| Prevotella nigrescens | 1 | 2012 | 1 | 0.020 |
Why?
|
| Vesicle-Associated Membrane Protein 3 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Prevotella intermedia | 1 | 2012 | 2 | 0.020 |
Why?
|
| Campylobacter rectus | 1 | 2012 | 2 | 0.020 |
Why?
|
| Treponema denticola | 1 | 2012 | 2 | 0.020 |
Why?
|
| Fusobacterium nucleatum | 1 | 2012 | 4 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 1976 | 528 | 0.020 |
Why?
|
| Bacteroides | 1 | 2012 | 21 | 0.020 |
Why?
|
| Porphyromonas gingivalis | 1 | 2012 | 23 | 0.020 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2012 | 40 | 0.020 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2012 | 27 | 0.020 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2012 | 14 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 62 | 0.020 |
Why?
|
| F-Box Proteins | 1 | 2012 | 24 | 0.020 |
Why?
|
| Triglycerides | 1 | 2014 | 524 | 0.020 |
Why?
|
| Nuclear Family | 2 | 2003 | 54 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2012 | 68 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2015 | 443 | 0.020 |
Why?
|
| Interleukin-33 | 1 | 2012 | 49 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 196 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2014 | 177 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 387 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2012 | 190 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2007 | 1063 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1993 | 171 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 514 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 2018 | 803 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 2005 | 137 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 1993 | 201 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 1937 | 0.020 |
Why?
|
| Drinking Water | 1 | 2012 | 80 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 32 | 0.020 |
Why?
|
| Finland | 2 | 2001 | 90 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2012 | 175 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 336 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2015 | 5077 | 0.020 |
Why?
|
| Interleukins | 1 | 2012 | 251 | 0.020 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2010 | 23 | 0.020 |
Why?
|
| Recombination, Genetic | 3 | 1998 | 198 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 143 | 0.020 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 39 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2009 | 6 | 0.020 |
Why?
|
| Menstruation | 1 | 2010 | 43 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 445 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2009 | 10 | 0.020 |
Why?
|
| Mannose-Binding Lectin | 1 | 2009 | 23 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 399 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1739 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 514 | 0.020 |
Why?
|
| C-Peptide | 1 | 2010 | 161 | 0.020 |
Why?
|
| Twins | 1 | 2010 | 253 | 0.020 |
Why?
|
| Hypertension, Portal | 1 | 2009 | 64 | 0.020 |
Why?
|
| Body Composition | 1 | 2013 | 665 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1524 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2010 | 353 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 50 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2009 | 165 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2008 | 5 | 0.020 |
Why?
|
| Puberty | 1 | 2009 | 146 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 482 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 39 | 0.020 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2006 | 7 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2010 | 343 | 0.020 |
Why?
|
| Fathers | 1 | 2008 | 50 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2011 | 759 | 0.020 |
Why?
|
| Monte Carlo Method | 2 | 2002 | 145 | 0.020 |
Why?
|
| Longevity | 1 | 2009 | 165 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2008 | 305 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 316 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2006 | 84 | 0.020 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2006 | 12 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2006 | 20 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2006 | 10 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2006 | 59 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2006 | 47 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 48 | 0.020 |
Why?
|
| Sweden | 1 | 2006 | 101 | 0.020 |
Why?
|
| Embolism | 1 | 2006 | 41 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 81 | 0.020 |
Why?
|
| Weight Lifting | 1 | 2005 | 34 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 1996 | 5766 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2006 | 206 | 0.010 |
Why?
|
| DNA Probes | 2 | 1997 | 60 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 413 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 85 | 0.010 |
Why?
|
| Statistical Distributions | 1 | 2004 | 8 | 0.010 |
Why?
|
| DNA Replication | 1 | 2006 | 242 | 0.010 |
Why?
|
| Adult Children | 1 | 2003 | 23 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 1324 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2003 | 143 | 0.010 |
Why?
|
| Consanguinity | 2 | 1994 | 49 | 0.010 |
Why?
|
| Skin Tests | 1 | 2003 | 100 | 0.010 |
Why?
|
| Radiography | 1 | 2006 | 834 | 0.010 |
Why?
|
| Systole | 1 | 2003 | 191 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 2003 | 42 | 0.010 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2003 | 13 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 68 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 145 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 359 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 82 | 0.010 |
Why?
|
| Cell Line | 2 | 2002 | 2847 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 595 | 0.010 |
Why?
|
| Mice | 4 | 2005 | 17775 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 126 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2002 | 56 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 2002 | 49 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2002 | 218 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 820 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2002 | 199 | 0.010 |
Why?
|
| Phylogeny | 1 | 2005 | 897 | 0.010 |
Why?
|
| Depressive Disorder, Major | 2 | 1976 | 361 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 161 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2002 | 392 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 2180 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1980 | 25 | 0.010 |
Why?
|
| Walking | 1 | 2005 | 514 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 2000 | 40 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 795 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 950 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 1242 | 0.010 |
Why?
|
| Biological Assay | 1 | 1980 | 123 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 869 | 0.010 |
Why?
|
| Cyclothymic Disorder | 2 | 1976 | 5 | 0.010 |
Why?
|
| Internet | 1 | 2004 | 652 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2003 | 434 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 1679 | 0.010 |
Why?
|
| Founder Effect | 1 | 1998 | 11 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 1863 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 562 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 2833 | 0.010 |
Why?
|
| Death Certificates | 1 | 1997 | 30 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2006 | 15514 | 0.010 |
Why?
|
| Accidents | 1 | 1997 | 39 | 0.010 |
Why?
|
| Depression | 2 | 1976 | 1402 | 0.010 |
Why?
|
| Malpractice | 1 | 1997 | 38 | 0.010 |
Why?
|
| Dibenzocycloheptenes | 1 | 1976 | 2 | 0.010 |
Why?
|
| Fluspirilene | 1 | 1976 | 1 | 0.010 |
Why?
|
| Penfluridol | 1 | 1976 | 1 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 1996 | 67 | 0.010 |
Why?
|
| Fluphenazine | 1 | 1976 | 5 | 0.010 |
Why?
|
| Nail-Patella Syndrome | 1 | 1976 | 1 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1976 | 32 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1976 | 40 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 1997 | 98 | 0.010 |
Why?
|
| Haloperidol | 1 | 1976 | 33 | 0.010 |
Why?
|
| Costa Rica | 1 | 1995 | 18 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1997 | 170 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1976 | 50 | 0.010 |
Why?
|
| Paranoid Disorders | 1 | 1975 | 2 | 0.010 |
Why?
|
| Hallucinations | 1 | 1975 | 31 | 0.010 |
Why?
|
| Swine | 1 | 1997 | 775 | 0.010 |
Why?
|
| Macrophages | 1 | 2002 | 1547 | 0.010 |
Why?
|
| Cause of Death | 1 | 1997 | 431 | 0.010 |
Why?
|
| Genes | 1 | 1995 | 230 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1975 | 100 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1975 | 180 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1993 | 49 | 0.010 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 1993 | 17 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1993 | 269 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1993 | 318 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1980 | 4204 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1992 | 19 | 0.010 |
Why?
|
| Turkey | 1 | 1992 | 22 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1992 | 72 | 0.010 |
Why?
|
| Ataxia | 1 | 1992 | 45 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1975 | 1060 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2670 | 0.010 |
Why?
|
| Microcephaly | 1 | 1992 | 98 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 1997 | 743 | 0.010 |
Why?
|
| Suicide | 1 | 1997 | 646 | 0.000 |
Why?
|
| Cysticercosis | 1 | 1969 | 3 | 0.000 |
Why?
|
| Cataract | 1 | 1992 | 213 | 0.000 |
Why?
|
| Brain Diseases | 1 | 1969 | 141 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1484 | 0.000 |
Why?
|
| Adjustment Disorders | 1 | 1976 | 5 | 0.000 |
Why?
|
| Psychophysiologic Disorders | 1 | 1976 | 10 | 0.000 |
Why?
|
| Neurocognitive Disorders | 1 | 1976 | 26 | 0.000 |
Why?
|
| Computers | 1 | 1976 | 68 | 0.000 |
Why?
|